LILRB3 and hematologic disorder: LILRB1 (also known as CD85J, ILT2, LIR1, and MIR7) and LILRB3 (CD85A, ILT5, LIR3, and HL9) are widely expressed on malignant cells of hematologic malignancies, such as AML, B cell leukemia/lymphoma, and T cell leukemia, where they intrinsically promote tumor progression [111].